The Global Drug Delivery Device Market is Forecast to Reach $22 Billion in 2017

Friday 21 October 2011, Amsterdam

The Global Drug Delivery Device Market is Forecast to Reach $22 Billion in 2017

The global market for drug delivery devices is forecast to exceed $22 billion by 2017 with a Compounded Annual Growth Rate (CAGR) of 4% from 2010 to 2017. Metered dose inhaler devices and the infusion systems market will be the largest drug delivery device segments, accounting for more than 96% of the total revenues. These categories are expected to grow at 4% and 6% CAGR during 2010 to 2017 to reach $13 billion and $8.3 billion respectively. The global drug delivery device market will be driven by new technological advancements, a shift towards needle-free technology and the adoption of cost cutting measures such as increased automation in the infusion system market. Furthermore, an increased level of control, accuracy and precision in infusion systems has led to a reduction in medication errors, thereby increasing market growth. The huge population afflicted with respiratory disorders such as asthma and chronic obstructive pulmonary disease will drive the metered dose inhaler market. Furthermore, according to the Asthma and Allergy Foundation of America, an estimated US population of 20 million suffers from asthma providing a huge opportunity for the growth of the drug delivery device market. Moreover, a growing number of clinical situations now demand a more sophisticated delivery system for effective treatment. In addition, a limitation of oral delivery is that the dosage is systemic rather than directed to a particular organ and the drug concentration is only at the optimal level in the body for a limited time. This need for specialized drug delivery devices for new drugs and therapeutics will lead to the growth of drug delivery device market.


GlaxoSmithKline was the Leading Company in the Global Drug Delivery Device Market in 2010

In 2010, GlaxoSmithKline plc, with a 26% share was the leader in the global drug delivery device market, followed by Boehringer Ingelheim and AstraZeneca International plc each with 8%. The other significant players in this market are Hospira Inc with a 6% share and CareFusion Corporation with 5%. These important players have launched advanced drug delivery products which have enabled them to strengthen their market presence. The market dominance of GlaxoSmithKline plc can be attributed to its major presence in the metered dose inhaler device market; the largest category in the drug delivery device market. The large patient pool suffering from respiratory disorders such as asthma, obstructive lung disorders, cystic fibrosis, pulmonary arterial hypertension, COPD and infectious pulmonary disease will provide huge opportunities for the companies. Furthermore, the improved efficacy of pressurized metered dose inhalers for administering bronchodilator aerosols to mechanically ventilated patients has accelerated market growth.


Metered Dose Inhaler Devices to Continue to be the Largest Category in the Global Drug Delivery Device Market in 2010

In 2010, the metered dose inhaler device contribution towards the global drug delivery device market was 59%. The global market for metered dose inhaler devices was valued at $9.6 billion in 2010 and is forecast to grow at a CAGR of 4% to reach $13 billion in 2017. The market is expected to be driven by the huge population suffering from asthma and Chronic Obstructive Pulmonary Disease (COPD) providing opportunities for the manufacturers of metered dose inhalers. In 2010, asthma affected 300 million people worldwide. Furthermore, according to the Asthma and Allergy Foundation of America, an estimated 20 million in the US suffer from asthma. The annual cost of therapy for asthma is estimated to be nearly $18 billion, of which direct costs account for nearly $10 billion, including hospitalization and indirect costs of $8 billion. Inhaled medicines have some shortcomings which have given companies a number of opportunities to gain market shares by product differentiation with an improved inhaler device. Furthermore, with the increasing number of similar molecules being launched and considerable unmet needs with regards to devices, there are a number of opportunities to gain market shares by differentiating from an improved inhaler device. This trend is due to continue in the near future and so the choice of device rather than choice of drug is set to become a driving force behind pulmonary disease management. Although this may not necessarily improve the efficacy of a drug, it will make it easier for the patient to inhale the drug from the device and to coordinate actuation with inhalation. The respiratory disease market is becoming increasingly saturated for most drug classes, namely inhaled steroids and bronchodilators. This will provide huge opportunities for manufacturers to invest in the metered dose inhalers device market.
 

Technological Advancements such as Microneedle Enhanced Drug Delivery and Smart Infusion Pumps to Drive Market

Microneedle enhanced drug delivery is an effective and painless way to deliver vaccines, injectable drugs, proteins and DNA to patients across the skin and into the dermal layers. The needles are micro-sized and help to deliver the drug painlessly by punching a series of microscopic holes in the outer layer of skin small enough to deliver macromolecules without reaching the nerves that cause sensation and pain. Transdermal drug delivery usage has been successfully proved in a number of applications, including pain management, congestive heart failure and hormone replacement. Furthermore, smart infusion pumps are now equipped with computerized prescriber order entry (CPOE), and Bar-Coded Medication Administration (BCMA) which has helped to prevent medication errors. Another recent piece of BCMA technology provides point-of-care verification to ensure the correct patient receives the correct medication. The Baclofen pump and implantable insulin pump allow the patient to receive ambulatory procedures and provides regulated doses for patients needing constant treatment. Thus, technological advancements taking place in the drug delivery device market are expected to drive the market.

The market is a consumer driven market whereby a product’s success depends upon its ease of use and the relevant technological advancements. Medical device manufacturers are increasingly recognizing this and are making small but significant design changes which enable a device to fit into a patient’s routine rather than other way around. Home monitoring devices have become smaller and less obtrusive and in some cases do not even require removal during bathing and sleeping. These changes allow patients to maintain their normal lifestyle, indirectly increasing compliance by reducing the number of adjustments that they previously had to make. Better patient outcomes and technological advancements have led to faster adoption rates for the new devices by surgeons. There have been significant advancements in the microneedle enhanced drug delivery device market and the smart infusion pump market.


About this new market study:
The report provides the market landscape, competitive landscape and market trend information on four drug delivery device market categories, namely central venous catheters, infusion systems, metered dose inhaler devices and needle-free injections. The report provides comprehensive information on the key trends affecting these categories and key analytical content on the market dynamics. The report also reviews the competitive landscape and gives a detailed analysis of the pipeline products in each category. The report also reviews the details of important merger and acquisition deals that have taken place in the drug delivery device market during the past four years. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.